Patients Reshaping the future of patient-centric drug development Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.
R&D GLP-1 RAs in CKM management: A Q&A with CORXEL GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.
Patients If GLP-1s work too well, what happens next for metabolic dis... What happens if GLP-1s work too well?
Market Access Fighting fake GLP-1s to protect patients & preserve trust Counterfeit drug promotion is a patient safety, brand equity, and public trust issue.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Patients Using patient data to fill in GLP-1 blind spots, with Phil J... At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.